Gilteritinib-d8

Modify Date: 2024-01-03 12:06:59

Gilteritinib-d8 Structure
Gilteritinib-d8 structure
Common Name Gilteritinib-d8
CAS Number 2377109-74-3 Molecular Weight 560.76
Density N/A Boiling Point N/A
Molecular Formula C29H36D8N8O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Gilteritinib-d8


Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

 Names

Name Gilteritinib-d8

 Gilteritinib-d8 Biological Activity

Description Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ASCO Annual Meeting.

[3]. Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565.

 Chemical & Physical Properties

Molecular Formula C29H36D8N8O3
Molecular Weight 560.76